ly2428757
Peptideexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2008 (NCT00804986)
Timeline
Indications
Studied for
Mechanism of action
GLP1R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ly2428757
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00853151 | Phase 1 | Feb 1, 2009 | Eli Lilly, Transition Therapeutics |
| NCT00804986 | Phase 2 | Dec 1, 2008 | Eli Lilly |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 2 | 2 | 2 | 2008 |
| Transition Therapeutics | For profit | 1 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1